Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond.
about
Addition of drug/s to a chemotherapy regimen for metastatic breast cancerAddition of drug/s to a chemotherapy regimen for metastatic breast cancerA Systematic Review of Clinical Outcomes and Prognostic Factors for Patients Undergoing Surgery for Spinal Metastases Secondary to Breast CancerMetabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic AgentsA multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer.A comparative analysis on the efficacy and safety of intaxel® and taxol® in advanced metastatic breast cancer.Diagnosis and surgical management of breast cancer metastatic to the spineInitiating oncogenic event determines gene-expression patterns of human breast cancer modelsPresent and future evolution of advanced breast cancer therapy.Combination chemotherapy for metastatic breast cancer.Novel pharmacological approaches in the treatment of breast cancer.Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts.The role of surrogate markers in the clinical development of antiretroviral therapy: a model for early evaluation of targeted cancer drugs.Poorer survival outcomes for male breast cancer compared with female breast cancer may be attributable to in-stage migration.Reversing multidrug resistance in breast cancer cells by silencing ABC transporter genes with nanoparticle-facilitated delivery of target siRNAs.Positive and negative prognostic variables for patients undergoing spine surgery for metastatic breast disease.Surgical treatment strategies and outcome in patients with breast cancer metastatic to the spine: a review of 87 patientsComparative analysis of xanafide cytotoxicity in breast cancer cell lines.Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines.Blood flow and glucose metabolism in stage IV breast cancer: heterogeneity of response during chemotherapy.Doxorubicin and vinorelbine act independently via p53 expression and p38 activation respectively in breast cancer cell lines.Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer.Albumin-bound paclitaxel: the benefit of this new formulation in the treatment of various cancers.Association of ABCB1, β tubulin I, and III with multidrug resistance of MCF7/DOC subline from breast cancer cell line MCF7.Lidamycin up-regulates the expression of thymidine phosphorylase and enhances the effects of capecitabine on the growth and pulmonary metastases of murine breast carcinoma.A clinical phase II study of a non-anthracycline sequential combination of cisplatin-vinorelbine followed by docetaxel as first-line treatment in metastatic breast cancer.Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate.Homocamptothecin-daunorubicin association overcomes multidrug-resistance in breast cancer MCF7 cells.Pharmacokinetics of gemcitabine combined with trastuzumab in patients with advanced breast cancer.Elevation of serum CEA and CA15-3 levels during antitumor therapy predicts poor therapeutic response in advanced breast cancer patients.Metastatic human breast cancer to the spine produces mechanical hyperalgesia and gait deficits in rodents.Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8.Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer.What Is the Role of Nanotechnology in Diagnosis and Treatment of Metastatic Breast Cancer? Promising Scenarios for the Near Future
P2860
Q24236594-4E496BE8-8E37-400A-A7EF-C8A2681DE44EQ24245443-5007BA0C-2AD3-489F-B7AB-BE878804C3A8Q26738942-26EF169D-39A4-4724-AC76-3C0D1451EA68Q26740567-0844CADC-1E70-4C52-A63D-36B8377092DAQ33399824-0A8C3DBB-CF84-4637-AB01-3B4220B0FE68Q33408664-721C07C1-93F8-4582-92E4-FAFCC55C13DFQ33409451-48F13939-4FF4-48BA-8D19-7396EB69D0ABQ34023628-6BB314D7-EFB1-4995-BA05-957ABE05E378Q34068051-BDB97781-0B5B-4D31-8EF5-BA7977764BD0Q34274925-1B459458-62EA-47D2-9FF4-741D47489ABDQ34734518-07948F63-84A2-4133-B72B-8A168AE2DDA8Q35143980-167BB901-9A09-46DE-AE7D-9B3D0B733953Q35683522-F8A0399F-0372-4DD9-97B1-FC6A09776ED7Q35740281-214274AC-E76C-4CB1-9EDD-89DFF3109051Q35751733-2C697722-8F95-4753-AE23-44D0E9DC1E85Q36027132-8FCAA0A8-BBC4-4644-8841-46304D9256B6Q36144917-F4E63237-8029-43AC-98E8-559D5EFEFCDAQ36384461-61D42E0F-C0BF-40B9-AA35-B3398C513BE8Q36608659-1AAF7EB0-A866-41CC-AB2B-9F7457CDD053Q36616289-CC2485DF-F6E5-4ED9-B731-96088A8D08F5Q37228097-D1BB3883-9369-4B89-8C19-A22ECAB86298Q37355092-EEE21063-5F34-4D08-886E-39AC614DC13CQ37402732-0E4EB6AE-A450-4DAA-9956-5C5947B4B9E6Q37875561-A7561F88-D677-435D-874C-9B25589AC59CQ38988566-9B40AA93-A23E-4090-9E3B-6B6AC22A0B5BQ39105402-8806067E-F224-453F-BD00-545C701E886AQ40462502-BA11E5D2-AB66-487D-A007-858922754C91Q43010569-EADA5738-6423-4D66-9587-A6127391E122Q44043973-6FE1D62C-D421-4199-9895-1F0E01821137Q46525474-7199383A-F4A0-45F2-B5B5-3AE0F43FFC48Q47552039-7E8FCEC2-4EA5-48B2-B984-B76EE99CCA43Q47792990-F29C29F5-9E50-4F51-8230-15F4CF03D3E7Q52730051-0FA2983F-39B5-4C9C-98CC-10B817E981B2Q54378040-DDE666C4-5D5E-490C-B5F2-73ACC57CCB1BQ59128232-BF32D575-8A76-427E-97DD-398557A9E982
P2860
Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond.
@ast
Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond.
@en
Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond.
@nl
type
label
Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond.
@ast
Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond.
@en
Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond.
@nl
prefLabel
Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond.
@ast
Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond.
@en
Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond.
@nl
P2093
P1433
P1476
Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond.
@en
P2093
Boehnke-Michaud L
Hortobagyi GN
P304
P356
10.1634/THEONCOLOGIST.6-2-133
P577
2001-01-01T00:00:00Z